Evidence map›Paper›PMID 40957494›Full record

ArticleNeurobiology of disease2025

Molecular polymorphism of tau aggregates in Pick's disease.

Jiliang Liu, Theresa Connors Stewart, Derek H Oakley, Bradley T Hyman, Manfred Burghammer, Marine Cotte, Lee Makowski

Abstract readCase Reports
In one paragraph

Article in Neurobiology of disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Jiliang LiuEuropean Synchrotron Radiation Facility, Grenoble 38043, France.
Theresa Connors StewartMassachusetts Alzheimer's Disease Research Center, Boston, MA, USA.
Derek H OakleyMassachusetts Alzheimer's Disease Research Center, Boston, MA, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA,USA; C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA, USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.
Bradley T HymanMassachusetts Alzheimer's Disease Research Center, Boston, MA, USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.
Manfred BurghammerEuropean Synchrotron Radiation Facility, Grenoble 38043, France.
Marine CotteEuropean Synchrotron Radiation Facility, Grenoble 38043, France.
Lee MakowskiBioengineering Department, Northeastern University, Boston, MA 02115, USA. Electronic address: l.makowski@northeastern.edu.

Funding

Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5M
Fibrillar polymorphs in human brain tissueRF1AG079946 · NIA · NORTHEASTERN UNIVERSITY · PI MAKOWSKI, LEE · 2023 to 2023
$2.1M
Localization of fibrillar polymorphs in human brain tissueR21AG068972 · NIA · NORTHEASTERN UNIVERSITY · PI MAKOWSKI, LEE · 2020 to 2020
$432k
NIA NIH HHS P30 AG062421NIA NIH HHS R21 AG068972NIA NIH HHS RF1 AG079946
6 · The paper itself

Abstract

backgroundTau protein is central to progressive neuropathological changes in many neurodegenerative diseases. Although the trajectory by which tau pathology spreads through neural networks has been studied, the molecular processes that drive disease are unknown. Characterizing these processes requires imaging tools that supplement neuropathological examination with information about the molecular organization of lesions while preserving details of their anatomical location. High-resolution cryo-electron microscope studies require isolation of material which destroys information on variation of lesion structure with location. Immunohistochemistry identifies principal constituents of lesions but provides little information about molecular organization. To bridge this knowledge gap, we have developed advanced biophysical imaging tools to probe, in situ, the molecular organization and composition of individual lesions within diseased brain tissue. Here we describe their use to assess the fibrillar organization and variation of elemental composition in tau-containing lesions within the brain of a 66-year-old male with dementia.

methodsWe used in situ micro X-ray diffraction (μXRD) to determine the aggregation state of tau in individual lesions and micro-X-ray fluorescence (μXRF) to determine the elemental content of these lesions. The information thus generated was combined with immunohistochemistry of serial sections that confirmed the principal molecular constituents of lesions and placed the results in a broader anatomical context.

resultsNeuropathological examination revealed classical forms of tau inclusions in the hippocampal formation including extensive Pick bodies in the dentate gyrus. μXRD data indicate that Pick bodies of the granular layer are relatively low in fibril content, whereas, surprisingly, the microscopically diffuse tau in the neuropil in adjacent CA4 and hilus regions exhibit far greater density of fibrillar signal. μXRF data show elevated levels of zinc, calcium and phosphorous relative to surrounding tissue in essentially all tau-containing lesions. Sulfur deposition appeared greater in areas exhibiting high fibrillar content. A second case of Pick's disease showed analogous results.

conclusionsThese observations demonstrate a correlation of lesion morphology with anatomical localization, degree of tau fibrillation and differential accumulation of metals and suggest that lesions containing different levels of tau fibrils harbor biochemically distinct microenvironments.

Indexed as

BrainPick Disease of the Braintau ProteinsAgedHumansMaleNeurofibrillary TanglesX-Ray DiffractionMAPT protein, humantau ProteinsPick bodiesPick's diseaseTauX-ray fluorescence microscopyX-ray microdiffraction

Identifiers

PMID40957494
PMCPMC12645749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.